These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8648772)

  • 1. The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma.
    Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Papapoulos SE; Hamdy NA
    J Urol; 1996 Jul; 156(1):122-6. PubMed ID: 8648772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer.
    Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Hamdy NA
    Prostate; 2002 Feb; 50(2):119-24. PubMed ID: 11816020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy.
    Nakashima J; Ozu C; Nishiyama T; Oya M; Ohigashi T; Asakura H; Tachibana M; Murai M
    Urology; 2000 Nov; 56(5):843-7. PubMed ID: 11068314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.
    Robinson D; Sandblom G; Johansson R; Garmo H; Stattin P; Mommsen S; Varenhorst E;
    J Urol; 2008 Jan; 179(1):117-22; discussion 122-3. PubMed ID: 17997442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
    Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audit and its impact in the management of advanced prostatic cancer.
    Rana A; Chisholm GD; Christodoulou S; McIntyre M; Elton RA
    Br J Urol; 1993 Oct; 72(4):478-83. PubMed ID: 8261306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of prostate-specific antigen minimum after orchidectomy in patients with stage C and D prostatic carcinoma.
    Riedl CR; Huebner WA; Mossig H; Ogris E; Pflueger H
    Br J Urol; 1995 Jul; 76(1):34-40. PubMed ID: 7544202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in metastatic prostate cancer.
    Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
    Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical parameters as prognostic factors in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Acta Oncol; 1995; 34(1):53-9. PubMed ID: 7865237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
    Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
    Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
    Hahn NM; Yiannoutsos CT; Kirkpatrick K; Sharma J; Sweeney CJ
    Clin Genitourin Cancer; 2014 Feb; 12(1):33-40.e4. PubMed ID: 24126237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.